Peptide news, explained for beginners
The peptide and GLP-1 industry in four numbers, ten decoded words and a dated record of what regulators actually did. Written for people new to this. No sellers, no doses, no advice.
ObesityWeek presentations are scheduled for November 14 to 17 (2026-11-14)
Novo Nordisk plans to present semaglutide and CagriSema data at ObesityWeek, 14 to 17 November. As of 11 November the meeting has not happened, so there are no conference results to report yet. Primary source
Survodutide cardiovascular trial meets its primary safety endpoint (2026-11-09)
In a large trial of adults with raised heart risk, the sponsor reports survodutide met its heart-safety goal against placebo. That is a safety result; it does not show the drug prevents heart attacks or strokes. Survodutide is still investigational. Primary source
HHS publishes a draft peptide compounding enforcement policy (2026-10-30)
HHS published a draft describing when it may not act against certain compounded peptides. A draft is not a final rule and not an approval, and compounded products are not FDA-approved. Primary source
Lilly reports retatrutide results in a type 2 diabetes comparison trial (2026-10-28)
In adults with type 2 diabetes not controlled on their current treatment, the company reports retatrutide lowered A1C and weight more than injectable semaglutide (Ozempic). These are the sponsor's first results, in one population; retatrutide is not approved. Primary source
Early ZP9830 results support further study of a Kv1.3 blocker (2026-10-19)
An early safety study in 32 healthy volunteers reported no serious or severe side effects over four weeks. That is early tolerability only: it says nothing yet about whether the drug helps people with autoimmune disease. Primary source
Import Alert 66-80: GLP-1 bulk drug substances and the green list (2026-10-09)
The FDA can hold imported GLP-1 bulk ingredients at the border without examining each shipment, unless the maker and ingredient are on the alert's exception list. Primary source
Petrelintide Phase 3 programme (ZUPREME) initiated (2026-09-22)
An investigational amylin analogue, not a GLP-1, entered Phase 3. Starting Phase 3 is not an approval. Primary source
Opinion: "the compounding loophole has become a business model" (2026-08-31)
This is one person's argument, not a finding or a regulator's decision. Primary source
FDA sends warning letters to five online peptide sellers (2026-08-24)
A warning letter goes to the seller and sets out what the FDA alleges. It is not a court finding, not a recall, and not a charge against anyone who bought. Primary source
UK MHRA authorises orforglipron (Foundayo) for weight management and type 2 diabetes (2026-08-10)
In the UK, orforglipron tablets are now authorised as a prescription-only medicine. The MHRA says it is not currently available through the NHS. Primary source
Stanford Medicine: why doctors worry about compounded GLP-1s (2026-07-16)
A university medical centre's explainer on why clinicians have safety concerns about compounded GLP-1 medicines. It is not a shop. Primary source
Retatrutide: TRIUMPH-1 and TRANSCEND-T2D-1 Phase 3 results presented (2026-06-06)
An investigational medicine reported Phase 3 results in obesity and in type 2 diabetes. It is not FDA-approved, and no approval elsewhere is listed in this item's sources. Primary source
FDA adverse event reports involving compounded semaglutide and tirzepatide (2026-05-31)
A report means someone told the FDA about a problem while using the drug. It does not show the drug caused it, and the FDA says reports for compounded versions are likely underreported. Primary source
FDA proposes not to put semaglutide, tirzepatide and liraglutide on the 503B bulks list (2026-05-01)
In the US, the FDA proposes that outsourcing facilities should not compound these three GLP-1s from bulk ingredients, finding no clinical need. It is a proposal, not a final decision. Primary source
Survodutide: first Phase 3 obesity results (SYNCHRONIZE-1) (2026-04-28)
An investigational medicine reported its first Phase 3 obesity results. It is not approved, and results from different trials cannot be compared directly. Primary source
FDA approves orforglipron (Foundayo) tablets for chronic weight management (2026-04-01)
A once-daily tablet that is a small molecule rather than a peptide. Oral GLP-1 medicines already existed: oral semaglutide, a peptide tablet, was approved earlier. Primary source
FDA clarifies compounding policies as GLP-1 supply stabilizes (2026-04-01)
In the US, the shortages that gave compounders more room to make these drugs are over, and FDA's temporary enforcement discretion tied to them has ended. Primary source
FDA sends 30 warning letters to telehealth marketers of compounded GLP-1s (2026-03-03)
The FDA warned 30 telehealth companies about claims implying a compounded product is the same as an approved one. These are the FDA's allegations, not a court finding. Primary source
CagriSema: US application filed, FDA decision pending (2025-12-18)
The application is filed, not approved. The decision timing is the company's guidance; the FDA has not published a date. Primary source
Educational use only, never medical advice. No doses.